

Louis B Nabors

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/443248/louis-b-nabors-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

160
papers

9,470
citations

52
h-index

95
g-index

174
ext. papers

10,921
ext. citations

5.2
avg, IF

5.51
L-index

#	Paper	IF	Citations
160	SRI-42127, a novel small molecule inhibitor of the RNA regulator HuR, potently attenuates glial activation in a model of lipopolysaccharide-induced neuroinflammation. <i>Glia</i> , 2022 , 70, 155-172	9	2
159	Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial.. <i>Neuro-Oncology Advances</i> , 2022 , 4, vdab186	0.9	1
158	High-dose methotrexate and rituximab induction regimen in immunocompetent patients with primary CNS lymphoma: a retrospective single-center study of survival predictors.. <i>Journal of Neuro-Oncology</i> , 2022 , 1	4.8	
157	Mitochondrial DNA sequence variation and risk of meningioma. <i>Journal of Neuro-Oncology</i> , 2021 , 155, 319-324	4.8	0
156	The versatile role of HuR in Glioblastoma and its potential as a therapeutic target for a multi-pronged attack.. <i>Advanced Drug Delivery Reviews</i> , 2021 , 181, 114082	18.5	2
155	Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071-22072 and CORE Trials. <i>Clinical Cancer Research</i> , 2021 ,	12.9	2
154	Digital measurement of functional status of patients with glioblastoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2016-2016	2.2	
153	Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors. <i>Cancer Research</i> , 2021 , 81, 2220-2233	10.1	8
152	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. <i>Clinical Cancer Research</i> , 2021 ,	12.9	4
151	Data Matching to Support Analysis of Cancer Epidemiology Among Veterans Compared With Non-Veteran Populations-An Exemplar in Brain Tumors. <i>JCO Clinical Cancer Informatics</i> , 2021 , 5, 985-994 ^{5.2}		
150	Mapping uncharted territory: a gene expression signature for precision glioblastoma therapeutics. <i>Neuro-Oncology</i> , 2020 , 22, 1713-1714	1	
149	Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug delivery. <i>Neuro-Oncology</i> , 2020 , 22, 1422-1424	1	9
148	Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial. <i>Clinical Cancer Research</i> , 2020 , 26, 1586-1594 ^{12.9}		56
147	Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. <i>Neuro-Oncology</i> , 2020 , 22, 601-612	1	12
146	An Update on Neurofibromatosis Type 1-Associated Gliomas. <i>Cancers</i> , 2020 , 12,	6.6	28
145	ELAVL1 Role in Cell Fusion and Tunneling Membrane Nanotube Formations with Implication to Treat Glioma Heterogeneity. <i>Cancers</i> , 2020 , 12,	6.6	6
144	Glioma-initiating cells at tumor edge gain signals from tumor core cells to promote their malignancy. <i>Nature Communications</i> , 2020 , 11, 4660	17.4	24

143	Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics. <i>International Journal of Cancer</i> , 2020 , 146, 739-748	7.5	14
142	Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. <i>Neurosurgery</i> , 2019 , 85, E607-E608 _{3,2}		10
141	Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational study. <i>PLoS Medicine</i> , 2019 , 16, e1002810	11.6	9
140	Anti-cancer effects of the HuR inhibitor, MS-444, in malignant glioma cells. <i>Cancer Biology and Therapy</i> , 2019 , 20, 979-988	4.6	24
139	Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	19
138	Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma. <i>Clinical Cancer Research</i> , 2019 , 25, 73-79	12.9	6
137	Methylmercury exposure, genetic variation in metabolic enzymes, and the risk of glioma. <i>Scientific Reports</i> , 2019 , 9, 10861	4.9	4
136	The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. <i>Neuro-Oncology</i> , 2019 , 21, 1498-1508	1	25
135	Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. <i>Neuro-Oncology</i> , 2019 , 21, 106-114	1	56
134	Updated phase I trial of anti-LAG-3 or anti-CD137 alone and in combination with anti-PD-1 in patients with recurrent GBM.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2017-2017	2.2	7
133	Safety and activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrent glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2027-2027	2.2	12
132	Management of Central Nervous System Tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 579-582	7.3	2
131	An early feasibility study of the Nativis Voyager device in patients with recurrent glioblastoma: first cohort in US. <i>CNS Oncology</i> , 2019 , 8, CNS30	4	4
130	Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials. <i>Clinical Cancer Research</i> , 2019 , 25, 1809-1816 ⁵⁹	12.9	59
129	Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?. <i>Journal of Neuro-Oncology</i> , 2018 , 138, 163-171	4.8	24
128	Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma. <i>Cancer Research</i> , 2018 , 78, 3002-3013	10.1	71
127	Associations of anticoagulant use with outcome in newly diagnosed glioblastoma. <i>European Journal of Cancer</i> , 2018 , 101, 95-104	7.5	7
126	Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2058-2058	2.2	9

125	ALLELE: A consortium for prospective genomics and functional diagnostics to guide patient care and trial analysis in newly-diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2003-2003	2.2	
124	ATIM-21. UPDATED RESULTS OF A PHASE I TRIAL OF ANTI-LAG-3 OR ANTI-CD137 ALONE AND IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH RECURRENT GBM. <i>Neuro-Oncology</i> , 2018 , 20, vi5-vi5 ¹		78
123	ACTR-18. PHASE II TRIAL OF TEMOZOLOMIDE AND TRC 102, BASE EXCISION REPAIR INHIBITOR, IN BEVACIZUMAB NAÏVE GLIOBLASTOMA AT FIRST RECURRENCE. <i>Neuro-Oncology</i> , 2018 , 20, vi15-vi15	1	1
122	NIMG-13. SEGMENTATION AND VOLUMETRIC ANALYSIS IMPROVES DETECTION OF PROGRESSION IN LOW GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2018 , 20, vi178-vi178	1	78
121	ACTR-15. SAFETY AND PRELIMINARY ACTIVITY OF PT2385, A FIRST-IN-CLASS HIF2-ALPHA INHIBITOR, PLANNED INTERIM ANALYSIS OF AN OPEN LABEL, SINGLE-ARM PHASE II STUDY IN PATIENTS WITH RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018 , 20, vi14-vi14	1	2
120	ACTR-14. PHASE I STUDY OF AZD1775 WITH RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) AND EVALUATION OF INTRATUMORAL DRUG DISTRIBUTION (IDD) IN PATIENTS WITH RECURRENT GBM. <i>Neuro-Oncology</i> , 2018 , 20, vi13-vi13	1	3
119	ACTR-20. A SMALL MOLECULE AXL INHIBITOR, BGB324 [FIRST-IN-HUMAN GBM SURGICAL PK TRIAL FOR RECURRENT TUMORS. <i>Neuro-Oncology</i> , 2018 , 20, vi15-vi15	1	78
118	Blocking PD1/PDL1 Interactions Together with MLN4924 Therapy is a Potential Strategy for Glioma Treatment. <i>Journal of Cancer Science & Therapy</i> , 2018 , 10, 190-197	5	12
117	Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. <i>Neuro-Oncology</i> , 2017 , 19, 845-852	1	30
116	Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. <i>Neuro-Oncology</i> , 2017 , 19, 1119-1126	1	82
115	Older age at the completion of linear growth is associated with an increased risk of adult glioma. <i>Cancer Causes and Control</i> , 2017 , 28, 709-716	2.8	4
114	The use of cannabidiol for seizure management in patients with brain tumor-related epilepsy. <i>Neurocase</i> , 2017 , 23, 287-291	0.8	17
113	Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 80, 1209-1217	3.5	80
112	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology</i> , 2017 , 18, 1373-1385	21.7	518
111	Hu antigen R (HuR) multimerization contributes to glioma disease progression. <i>Journal of Biological Chemistry</i> , 2017 , 292, 16999-17010	5.4	27
110	NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 1331-1345	7.3	106
109	Repeatability of F-FLT PET in a Multicenter Study of Patients with High-Grade Glioma. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 393-398	8.9	24
108	Efficacy analysis of ABT-414 with or without temozolomide (TMZ) in patients (pts) with EGFR-amplified, recurrent glioblastoma (rGBM) from a multicenter, international phase I clinical trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2003-2003	2.2	7

107	Phase I study of AZD1775 with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) and evaluation of intratumoral drug distribution (IDD) in patients with recurrent GBM.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2005-2005	2.2	2
106	Final results from the dose-escalation stage of a phase 1/2 trial of TPI 287, a brain penetrable microtubule inhibitor, plus bevacizumab in patients with recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2021-2021	2.2	1
105	Individualized screening trial of innovative glioblastoma therapy (INSIGHt).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS2079-TPS2079	2.2	12
104	Implementation and utilization of the molecular tumor board to guide precision medicine. <i>Oncotarget</i> , 2017 , 8, 57845-57854	3.3	41
103	Reply to F. Felix et al and M.F. Fay et al. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3107-8	2.2	1
102	Primary Sellar Rhabdomyosarcoma Arising in Association With a Pituitary Adenoma. <i>International Journal of Surgical Pathology</i> , 2016 , 24, 753-756	1.2	5
101	Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. <i>Human Gene Therapy Clinical Development</i> , 2016 , 27, 69-78	3.2	83
100	Pilot Study to Explore the Accuracy of Current Prediction Equations in Assessing Energy Needs of Patients with Newly Diagnosed Glioblastoma Multiforme. <i>Nutrition and Cancer</i> , 2016 , 68, 926-34	2.8	1
99	Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2016 , 34, 731-9 ^{2.2}	2.2	108
98	Analgesic use and the risk of primary adult brain tumor. <i>European Journal of Epidemiology</i> , 2016 , 31, 917-251	2.2	8
97	Phase 1/2 trial of bevacizumab plus TPI 287, a brain penetrable anti-microtubule agent, in patients with recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2055-2055	2.2	2
96	Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2542-2542	2.2	5
95	Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. <i>Oncotarget</i> , 2016 , 7, 15018-32	3.3	49
94	Complications from pharmacotherapy. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2016 , 134, 235-50	3	0
93	Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2015 , 122, 585-93	4.8	10
92	Growth factor dependent regulation of centrosome function and genomic instability by HuR. <i>Biomolecules</i> , 2015 , 5, 263-81	5.9	10
91	Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. <i>Neuro-Oncology</i> , 2015 , 17, 708-17	1	148
90	Complementary therapy and survival in glioblastoma. <i>Neuro-Oncology Practice</i> , 2015 , 2, 122-126	2.2	19

89	Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3186-92	2.2	13
88	Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2015 , 125, 123-31	4.8	6
87	Brain tumor risk according to germ-line variation in the MLLT10 locus. <i>European Journal of Human Genetics</i> , 2015 , 23, 132-4	5.3	12
86	Cognitive Predictors of Reasoning through Treatment Decisions in Patients with Newly Diagnosed Brain Metastases. <i>Journal of the International Neuropsychological Society</i> , 2015 , 21, 412-8	3.1	8
85	Capacity of patients with brain metastases to make treatment decisions. <i>Psycho-Oncology</i> , 2015 , 24, 1448-55	3.9	18
84	SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma. <i>Science Translational Medicine</i> , 2015 , 7, 289ra86	17.5	137
83	IMCT-08ReACT: LONG-TERM SURVIVAL FROM A RANDOMIZED PHASE II STUDY OF RINDOPEPIMUT (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2015 , 17, v109.1-v109	1	17
82	Impairment of medical decisional capacity in relation to Karnofsky Performance Status in adults with malignant brain tumor. <i>Neuro-Oncology Practice</i> , 2015 , 2, 13-19	2.2	13
81	Ipilimumab-induced encephalopathy with a reversible splenic lesion. <i>Cancer Immunology Research</i> , 2015 , 3, 598-601	12.5	44
80	Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2015 , 17, 430-9	1	78
79	ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2009-2009	2.2	45
78	Timed-sequential therapy with mibefradil and temozolomide in patients with recurrent high-grade gliomas: A phase I Adult Brain Tumor Consortium study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2033-2033 ²		
77	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 1100-8	21.7	629
76	Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters. <i>Journal of Neuro-Oncology</i> , 2014 , 120, 361-70 ^{4.8}		17
75	Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro. <i>Journal of Neuro-Oncology</i> , 2014 , 118, 61-72	4.8	59
74	Reproductive factors and risk of primary brain tumors in women. <i>Journal of Neuro-Oncology</i> , 2014 , 118, 297-304	4.8	37
73	The role of Src family kinases in growth and migration of glioma stem cells. <i>International Journal of Oncology</i> , 2014 , 45, 302-10	4.4	37
72	Role of MRI in primary brain tumor evaluation. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 1561-8	7.3	14

71	A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. <i>Molecular Therapy</i> , 2014 , 22, 1048-55	11.7	170
70	Hypofractionated stereotactic radiosurgery with concurrent bevacizumab for recurrent malignant gliomas: the University of Alabama at Birmingham experience. <i>Neuro-Oncology Practice</i> , 2014 , 1, 172-177 ^{2.2}		8
69	Cognition in patients with newly diagnosed brain metastasis: profiles and implications. <i>Journal of Neuro-Oncology</i> , 2014 , 120, 179-85	4.8	35
68	Circadian pathway genes in relation to glioma risk and outcome. <i>Cancer Causes and Control</i> , 2014 , 25, 25-32	2.8	35
67	Early life exposures and the risk of adult glioma. <i>European Journal of Epidemiology</i> , 2013 , 28, 753-8	12.1	12
66	Toenail iron, genetic determinants of iron status, and the risk of glioma. <i>Cancer Causes and Control</i> , 2013 , 24, 2051-8	2.8	6
65	SWI/SNF gene variants and glioma risk and outcome. <i>Cancer Epidemiology</i> , 2013 , 37, 162-5	2.8	10
64	Anthropometric factors in relation to risk of glioma. <i>Cancer Causes and Control</i> , 2013 , 24, 1025-31	2.8	33
63	Mutant tristetrapirolin: a potent inhibitor of malignant glioma cell growth. <i>Journal of Neuro-Oncology</i> , 2013 , 113, 195-205	4.8	18
62	Prediagnostic body weight and survival in high grade glioma. <i>Journal of Neuro-Oncology</i> , 2013 , 114, 79-84.8		29
61	NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. <i>Neuro-Oncology</i> , 2013 , 15, 490-6	1	63
60	Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3212-8	2.2	392
59	A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. <i>Clinical Cancer Research</i> , 2013 , 19, 900-8	12.9	85
58	Sex hormone-dependent attenuation of EAE in a transgenic mouse with astrocytic expression of the RNA regulator HuR. <i>Journal of Neuroimmunology</i> , 2012 , 246, 34-7	3.5	7
57	An exploratory analysis of common genetic variants in the vitamin D pathway including genome-wide associated variants in relation to glioma risk and outcome. <i>Cancer Causes and Control</i> , 2012 , 23, 1443-9	2.8	32
56	Primary central nervous system angiosarcoma: two case reports. <i>Journal of Medical Case Reports</i> , 2012 , 6, 251	1.2	12
55	A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). <i>Cancer</i> , 2012 , 118, 5601-7	6.4	95
54	Rare TP53 genetic variant associated with glioma risk and outcome. <i>Journal of Medical Genetics</i> , 2012 , 49, 420-1	5.8	33

53	SSBP2 variants are associated with survival in glioblastoma patients. <i>Clinical Cancer Research</i> , 2012 , 18, 3154-62	12.9	18
52	Phosphoregulation of the RNA-binding protein Hu antigen R (HuR) by Cdk5 affects centrosome function. <i>Journal of Biological Chemistry</i> , 2012 , 287, 32277-87	5.4	38
51	Primary Melanotic Tumors of the Central Nervous System 2012 , 709-714		
50	Cilengitide: an RGD pentapeptide α and β integrin inhibitor in development for glioblastoma and other malignancies. <i>Future Oncology</i> , 2011 , 7, 339-54	3.6	82
49	Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2011 , 55, 77-81	1.7	64
48	Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. <i>Neuro-Oncology</i> , 2011 , 13, 1324-30	1	31
47	Cancer susceptibility variants and the risk of adult glioma in a US case-control study. <i>Journal of Neuro-Oncology</i> , 2011 , 104, 535-42	4.8	68
46	Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2011 , 105, 375-81	4.8	13
45	A functional polymorphism in the pre-miR-146a gene is associated with risk and prognosis in adult glioma. <i>Journal of Neuro-Oncology</i> , 2011 , 105, 639-46	4.8	62
44	The RNA-binding protein HuR promotes glioma growth and treatment resistance. <i>Molecular Cancer Research</i> , 2011 , 9, 648-59	6.6	101
43	Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. <i>Clinical Cancer Research</i> , 2010 , 16, 2443-9	12.9	347
42	Capacity to consent to research participation in adults with malignant glioma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3844-50	2.2	28
41	Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome. <i>Clinical Cancer Research</i> , 2010 , 16, 2890-8	12.9	25
40	A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. <i>Archives of Neurology</i> , 2010 , 67, 313-9		47
39	Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2010 , 100, 95-103	4.8	63
38	Treatment of primary CNS lymphoma with high-dose methotrexate in immunocompetent pediatric patients. <i>Pediatric Blood and Cancer</i> , 2010 , 55, 1227-30	3	9
37	Amyotrophic lateral sclerosis-linked mutant SOD1 sequesters Hu antigen R (HuR) and TIA-1-related protein (TIAR): implications for impaired post-transcriptional regulation of vascular endothelial growth factor. <i>Journal of Biological Chemistry</i> , 2009 , 284, 33989-98	5.4	48
36	Medical decision-making capacity in patients with malignant glioma. <i>Neurology</i> , 2009 , 73, 2086-92	6.5	85

35	Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. <i>Molecular Therapy</i> , 2009 , 17, 199-207	11.7	278
34	Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma. <i>Neuro-Oncology</i> , 2009 , 11, 357-67	1	46
33	Isolated central nervous system posttransplant lymphoproliferative disorder treated with high-dose intravenous methotrexate. <i>American Journal of Transplantation</i> , 2009 , 9, 1243-8	8.7	30
32	High-resolution longitudinal assessment of flow and permeability in mouse glioma vasculature: Sequential small molecule and SPIO dynamic contrast agent MRI. <i>Magnetic Resonance in Medicine</i> , 2009 , 61, 615-25	4.4	41
31	Distress and quality of life in primary high-grade brain tumor patients. <i>Supportive Care in Cancer</i> , 2009 , 17, 793-9	3.9	62
30	Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression. <i>Clinical Cancer Research</i> , 2008 , 14, 4694-704	12.9	140
29	The ING4 tumor suppressor attenuates NF-kappaB activity at the promoters of target genes. <i>Molecular and Cellular Biology</i> , 2008 , 28, 6632-45	4.8	91
28	Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas. <i>Neuro-Oncology</i> , 2008 , 10, 608-16	1	25
27	Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5610-7	2.2	384
26	Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 1225-35	5.9	152
25	Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1651-7	2.2	250
24	Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3644-50	2.2	162
23	Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006 , 65, 1192-9	4	79
22	A novel technique to quantify glioma tumor invasion using serial microscopy sections. <i>Journal of Neuroscience Methods</i> , 2006 , 153, 183-9	3	3
21	1p/19q chromosome deletions in metastatic oligodendroglioma. <i>Journal of Neuro-Oncology</i> , 2006 , 80, 203-7	4.8	21
20	Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM). <i>Journal of Neuro-Oncology</i> , 2006 , 80, 261-74	4.8	40
19	The ELAV RNA-stability factor HuR binds the 5' untranslated region of the human IGF-1R transcript and differentially represses cap-dependent and IRES-mediated translation. <i>Nucleic Acids Research</i> , 2005 , 33, 2962-79	20.1	98
18	IL-1beta induces stabilization of IL-8 mRNA in malignant breast cancer cells via the 3' untranslated region: Involvement of divergent RNA-binding factors HuR, KSRP and TIAR. <i>International Journal of Cancer</i> , 2005 , 113, 911-9	7.5	81

17	Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells. <i>Cancer Research</i> , 2005 , 65, 5535-43	10.1	86
16	Treatment of adults with recurrent malignant glioma. <i>Expert Review of Neurotherapeutics</i> , 2005 , 5, 509-14	3	13
15	A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. <i>Molecular Therapy</i> , 2004 , 10, 958-66	11.7	332
14	Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. <i>Clinical Cancer Research</i> , 2004 , 10, 5643-6	12.9	165
13	Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. <i>Neuro-Oncology</i> , 2004 , 6, 21-7	1	86
12	Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: quality and analysis results of a phase I trial. <i>Journal of Magnetic Resonance Imaging</i> , 2004 , 20, 913-22	5.6	73
11	Tumor necrosis factor alpha induces angiogenic factor up-regulation in malignant glioma cells: a role for RNA stabilization and HuR. <i>Cancer Research</i> , 2003 , 63, 4181-7	10.1	95
10	Human cytomegalovirus infection and expression in human malignant glioma. <i>Cancer Research</i> , 2002 , 62, 3347-50	10.1	466
9	Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. <i>Molecular Cancer Therapeutics</i> , 2002 , 1, 1139-45	6.1	25
8	Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. <i>Journal of Clinical Investigation</i> , 2001 , 108, 1657-65	15.9	338
7	Analysis of the 5' end of the mouse Elavl1 (mHuA) gene reveals a transcriptional regulatory element and evidence for conserved genomic organization. <i>Gene</i> , 2000 , 242, 125-31	3.8	16
6	Hu antigen specificities of ANNA-I autoantibodies in paraneoplastic neurological disease. <i>Journal of Autoimmunity</i> , 1999 , 13, 435-43	15.5	53
5	HuR, a novel target of anti-Hu antibodies, is expressed in non-neural tissues. <i>Journal of Neuroimmunology</i> , 1998 , 92, 152-9	3.5	32
4	Magnetic resonance cisternography in the diagnosis of delayed iatrogenic cerebrospinal fistula: a case report 1997 , 7, 244-7		1
3	Quantitative immunocytochemistry using an image analyzer. I. Hardware evaluation, image processing, and data analysis. <i>Journal of Neuroscience Methods</i> , 1988 , 26, 1-23	3	105
2	Quantitative immunocytochemistry using an image analyzer. II. Concentration standards for transmitter immunocytochemistry. <i>Journal of Neuroscience Methods</i> , 1988 , 26, 25-34	3	40
1	Catheter placement selection for convection-enhanced delivery of therapeutic agents to brain tumors. <i>F1000Research</i> , 9 , 1415	3.6	2